Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and ...

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals ...

The biotech’s mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to ...

Mizuho Americas healthcare equity strategist Jared Holz joins Market Domination with Josh Lipton and Julie Hyman to explain why he's telling clients to stay away from the stock for now.

“It’s just a bad time to be in the vaccine business,” said Jared Holz, healthcare strategist at financial firm Mizuho. “The proclivity that this administration has shown is certainly not ...

The biotech giant that soared during Operation Warp Speed now faces regulatory hurdles, political scepticism, and dwindling ...

Tariffs, executive orders, and FTC probes are just some of the problems piling up for the pharmaceutical industry. Trump's actions are pressuring a historically "safe" sector.

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

how much is being shifted over to the U.S.,” said Jared Holz, a health care analyst with Mizuho Americas, the American branch of Tokyo-based financial holding company Mizuho Financial Group. “ ...

"The stock shakes off almost every fundamental issue/set-back and still manages to outperform most peers," wrote Mizuho healthcare equity strategist Jared Holz in a note to clients on Nov. 10 ...